About Evolus
Evolus is a company based in Irvine (United States) founded in 2012. Evolus has raised $500 thousand across 3 funding rounds from investors including Daewoong Pharmaceutical. The company has 332 employees. Evolus offers products and services including Jeuveau and Evolysse. Evolus operates in a competitive market with competitors including Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
- Headquarter Irvine, United States
- Employees 332
- Stage Public
- SectorsHealthcare
- Website category Finance · Investing
- Email••••••••
- Website evolus.com
- Social LinkedIn X Facebook Instagram
- Legal Name Evolus, Inc. Common Stock
- Annual Revenue$297.18 M (USD)11.61as on Dec 31, 2025
- Net Profit-$51.64 M (USD)-2.42as on Dec 31, 2025
- EBITDA-$28.86 M (USD)-36.02as on Dec 31, 2025
- Total Equity Funding$500K (USD)
in 3 rounds
- Latest Funding Round$20.01M (USD), Post-IPO
Apr 2022
- Investors
- Employee Count332
Products & Services of Evolus
Evolus offers a comprehensive portfolio of products and services, including Jeuveau and Evolysse.
Improves appearance of moderate to severe frown lines temporarily.
Softens dynamic facial wrinkles and folds via injection.
Funding Insights of Evolus
Evolus has successfully raised a total of $500K across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20.01 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $500,000
- Total Rounds 3
- Last Round Post-IPO — $20.01M
- First Round $500,000
(Mar 2013)
- Investors Count 1
All 3 funding rounds of Evolus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $20.01M | Post-IPO | – | – | – |
| Jul 2020 | $40M | Post-IPO | – | – | |
| Mar 2013 | $500,000 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Evolus
Evolus has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Daewoong Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapies for gastrointestinal disorders and related diseases are developed. | 1945 | daewoong.com | Seoul, South Korea |
Investor details for Evolus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Evolus
132 people are tracked at Evolus (46 in leadership, 7 in board & advisors, 79 in team); the tracked headcount is 332.
| Name | Role | Group |
|---|---|---|
Murthy Simhambhatla | CEO | Leadership |
Jose Bimont | Senior Vice President Digital Marketing And Innovation | Leadership |
Rui Avelar | Chief Medical Officer & Head of Research & Development | Leadership |
Alexandra Hargreaves | Executive Director, Global Supply Chain | Leadership |
David Moatazedi | President & CEO | Leadership |
Michael Poe | Vice President Creative | Leadership |
Amber Leigh Pappas | Director Medical Affairs | Leadership |
Susan K. | Key Accounts Director | Leadership |
Kathleen Burkett | VP Accounting | Leadership |
Victoria García Ugía | Commercial Business Excellence Director | Leadership |
Philipp Enning | Executive Director, Sales Excellence & Analytics | Leadership |
Sean Loughlin | Executive Director, Corporate Development | Leadership |
Yasmine Ahrestani | Director, Talent | Leadership |
Kellie Lao | Executive Director, Consumer Marketing | Leadership |
Chayna Bhaskar | Executive Director, Human Resources | Leadership |
Kristen Jauregui | Sr. Art Director | Leadership |
Nareg Sagherian | Vice President, Global Head Of Investor Relations And Corporate Communications (nasdaq: Eols) | Leadership |
Kourtney Cavallio | Vice President, Upstream & Commercial Marketing | Leadership |
Dane Osborn | Art Director | Leadership |
Rose Monroe | Exec. Director - Clinical Operations | Leadership |
112 more people are available in the full profile.
Complete people profiles for Evolus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Evolus
Evolus is a publicly listed company on the NASDAQ with ticker symbol EOLS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Feb 2018
- Listed onNASDAQ: EOLS
- Listed entityEvolus, Inc. Common Stock
- Exchange sectorHealth technology
- ISINUS30052C1071
- Share price$7.80 (+0.78% on the day) · 2026-10-08
- Market capitalisation$515.2M
- EPS (diluted, trailing year)$-0.53
- Volume (last session)1,077,997
Financials of Evolus
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $297.2M | -$51.6M | -$28.9M |
| 2024 | $266.3M | -$50.4M | -$21.2M |
| 2023 | $202.1M | -$61.7M | -$30.2M |
| 2022 | $148.6M | -$74.4M | -$55.1M |
| 2021 | $99.7M | -$46.8M | -$57.3M |
Detailed financial statements for Evolus
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Evolus
4 dated milestones of Evolus across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Evolus is founded.
- Funding First funding round of $500K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $20.0M.
Competitors of Evolus
Evolus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Castle Creek Pharma, Dermavant, Sol-Gel Technologies and Bausch Health, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| castlecreekpharma.com | 2015 | Basking Ridge, United States | $663.15M | 72 | Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | |
| dermavant.com | 2016 | Phoenix, United States | $160M | – | Small molecule therapeutics for inflammatory skin diseases are developed. | |
| sol-gel.com | 1998 | United States | $9M | – | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. | |
| bauschhealth.com | 1960 | Laval, Canada | – | 808 | Therapeutics for multiple diseases including dermatology and neurology are developed. | |
| hugel.co.kr | 2001 | Chuncheon-si, South Korea | – | – | Therapeutics in aesthetics are developed, including botulinum toxin products. | |
| sofregen.com | 2014 | Medford, United States | $17.8M | 8 | Silk-derived biomaterials are developed for soft tissue repair in surgery. | |
| kythera.com | 2005 | Calabasas, United States | $144.82M | 113 | Prescription products for aesthetic medicine are developed and commercialized. | |
| pyramidbio.com | 2015 | Waltham, United States | $71.19M | 3 | Small molecules are developed for dermatology and oncology treatments. |
Detailed competitors of Evolus
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Evolus
The website of Evolus (evolus.com) receives about 36.5K visits a month and ranks #656,968 among all websites worldwide, #6,452 in Investing.
- Monthly visits36.5K
- Unique visitors11.8K
per month
- Global rank#656,968
among all websites
- Category rank#6,452
Finance · Investing
- Bounce rate36%
- Pages per visit4.5
- Average visit2 min 18 sec
- DevicesDesktop 59% · Mobile 41%
Latest news on Evolus
Complete news archive for Evolus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Evolus
10 companies that operate in the same segment as Evolus (Dermatology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Developer of drugs for treating dermatology diseases | 1908 | Copenhagen, Denmark | USD 560.38 M | – | – | |
Skincare, beauty, and wellness services provided by VLCC across multiple countries. | 1989 | Delhi, Delhi, India | – | – | – | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608 M | – | – | |
Immunotherapeutic solutions for dermatological conditions are developed. | 2016 | Westlake Village, California, United States | USD 94.5 M | USD 376.07 M | 342 | |
Targeted small molecules are developed for oncology treatments. | 2010 | Singapore, Singapore | USD 100 M | – | – | |
Pharmaceutical formulations for dermatology, gastroenterology, and wellness are manufactured. | 2014 | Pune, Maharashtra, India | USD 25.97 M | USD 18.15 M | 508 | |
Novel dermatologic therapies are developed for skin conditions. | 2012 | Malvern, Pennsylvania, United States | USD 82 M | USD 7.83 M | 64 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Evolus
Evolus was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Evolus is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Murthy Simhambhatla is the current CEO of Evolus.
Evolus is a funded company, having raised a total of $500K across 3 funding rounds to date. The company's 1st funding round was a Seed of $500K, raised on Mar 2013.
Evolus has 332 employees.
Annual revenue of Evolus is $297.18M as on Dec 31, 2025.
Evolus was founded in 2012 and is headquartered in Irvine, United States. Operations center on the development of self-pay aesthetic products within the biotechnology sector. The lead product candidate, DWP-450, an injectable 900 kDa purified botulinum toxin type A complex, is currently in Phase II clinical trials for moderate-to-severe glabellar lines. Focus remains on advancing injectable aesthetic solutions.
Evolus's top competitors include Revance Therapeutics, Dermavant and Bausch Health.
Evolus offers Jeuveau and Evolysse.
Yes, Evolus is publicly traded on NASDAQ under the ticker symbol EOLS.
Evolus has 1 investor. Key investors include Daewoong Pharmaceutical.
Evolus operates through Evolus, Inc..